• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[The midterm evolution in the percutaneous closure of ductus arteriosus with the Rashkind prosthesis].

作者信息

Zabala Argüelles J I, García Fernández J, Zunzunegui Martínez J L, Camino López M, Maroto Alvaro E, Maroto Monedero C

机构信息

Departamento de Pediatría, Hospital General Universitario Gregorio Marañón, Madrid.

出版信息

An Esp Pediatr. 1996 Apr;44(4):332-6.

PMID:8849082
Abstract

Background percutaneous PDA occlusion has been proposed as a valid therapeutic alternative to surgical closure. Between April 1990 and July 1994, 44 patients underwent percutaneous PDA occlusion. Thirteen patients were less than 18 months old and weighed 8.7 +/- 3.2 Kg (Group I). Thirty-one patients, older than 18 months of age, had a mean weight of 36.8 +/- 20.6 Kg (Group II). Four patients in group I and two in group II had associated cardiac anomalies Residual shunt after percutaneous occlusion was studied by color Doppler. Fifty-one occluding devices were used. Forty-nine were implanted and there were two device embolizations. Twelve devices were implanted in group I. One device needed surgical removal from the right ventricle where it had embolized. In group II, 31 devices were implanted and one embolized to the descending aorta and was percutaneously removed through the femoral artery sheath. In two patients of group I and four of group II, a second device was implanted. The total occlusion rate immediately after implantation at 24 hours and at 6 months was 75%, 83% and 83% in group I and 64.5%, 77% and 84% in group II. After implantation of a second device the total occlusion rate without residual shunt reached 100% in group I (after 16 +/- 12 months follow-up) and 97% in group II (after 23 +/- 16 months of follow-up). We conclude that percutaneous ductal occlusion with a Rashkind device is a valid therapeutic alternative to surgical closure in all age groups.

摘要

相似文献

1
[The midterm evolution in the percutaneous closure of ductus arteriosus with the Rashkind prosthesis].
An Esp Pediatr. 1996 Apr;44(4):332-6.
2
[Percutaneous closure of patent ductus arteriosus with the Rashkind device].[使用拉什金德装置经皮闭合动脉导管未闭]
Rev Port Cardiol. 1994 Jun;13(6):493-501, 476.
3
[A comparative study of Rashkind, Grifka and coil devices in percutaneous closing of patent ductus arteriosus].[Rashkind、Grifka和线圈装置经皮闭合动脉导管未闭的比较研究]
Arch Inst Cardiol Mex. 2000 Mar-Apr;70(2):167-72.
4
[The transcatheter closure of patent ductus arteriosus. The initial experience].
Arch Inst Cardiol Mex. 1993 Nov-Dec;63(6):493-9.
5
Experience with 205 procedures of transcatheter closure of ductus arteriosus in 182 patients, with special reference to residual shunts and long-term follow-up.182例患者205次动脉导管未闭经导管封堵术的经验,特别提及残余分流及长期随访。
J Thorac Cardiovasc Surg. 1992 Dec;104(6):1721-7.
6
Percutaneous closure of small patent ductus arteriosus: comparison of Rashkind double-umbrella device and occluding spring coils.
Cathet Cardiovasc Diagn. 1996 Sep;39(1):44-8. doi: 10.1002/(SICI)1097-0304(199609)39:1<44::AID-CCD9>3.0.CO;2-2.
7
[The percutaneous closure of the ductus arteriosus in adults].[成人动脉导管未闭的经皮封堵术]
Rev Port Cardiol. 1999 Mar;18(3):255-9.
8
Percutaneous closure of window-type patent ductus arteriosus: using the CardioSEAL and STARFlex devices.经皮闭合窗型动脉导管未闭:使用CardioSEAL和STARFlex装置
Tex Heart Inst J. 2003;30(3):236-9.
9
[Therapeutic catheterization: the percutaneous closure of a persistent ductus arteriosus and of interatrial communication].[治疗性导管插入术:经皮闭合动脉导管未闭和房间隔交通]
Rev Esp Cardiol. 1992 Jan;45(1):42-50.
10
[Transcatheter closure of persistent ductus arteriosus].[经导管闭合动脉导管未闭]
Tidsskr Nor Laegeforen. 2003 Dec 4;123(23):3358-60.